Can you take semaglutide without injection?

What exactly is the injection-free semaglutide option?

Wegovy tablets contain the same active ingredient (semaglutide) as the weekly injection pen, but the molecule is paired with a compound called SNAC that helps it absorb through the stomach lining. The result is a once-daily capsule taken first thing in the morning, before breakfast, with a small amount of plain water (roughly up to 120ml). No needle. No sharps bin. The MHRA approved it on 11 June 2026, making the UK the first country in Europe to license an oral GLP-1 medicine for weight management. You can read the full background on the Wegovy treatment page, which covers both forms side by side.

The dosing schedule starts at 1.5mg and steps up through 4mg and 9mg to a 25mg maintenance dose, with at least a month at each level. That escalation exists for the same reason the injection pen starts low: giving your body time to settle. The tablet is swallowed whole; no chewing, no splitting. After taking it, you wait at least 30 minutes before any food, coffee or other oral medicines. That morning routine is the main practical discipline the tablet asks of you, before the kettle has even boiled, you are done.

Storage is straightforward: unlike the injection pen, the tablet needs no refrigeration. Room temperature is fine, which makes it genuinely convenient for travel or anyone without reliable fridge space. For precise storage instructions and the full list of ingredients, the prescribing information on the Medicines compendium (eMC) is the authoritative reference.

How does the tablet compare to the injection for weight loss?

The weekly injection form of semaglutide, covered in detail on the semaglutide injection page, produced an average weight reduction of around 15% over 68 weeks in the STEP 1 phase-3 trial at the 2.4mg maintenance dose. The oral tablet was studied in the OASIS 4 trial (307 adults with obesity or overweight plus at least one weight-related condition, without type 2 diabetes, over 64 weeks) and produced an average loss of around 13.6% versus roughly 2.4% for placebo. Among participants who remained fully adherent, the figure reached approximately 17%. That adherent-population result is not the plain average; it applies specifically to those who kept to the regimen throughout the trial.

Head-to-head data between the tablet and the injection is limited, so drawing firm conclusions about which form works better for a given individual is not currently possible. What the trial does show is that the tablet produces clinically meaningful weight loss. Whether that is the right figure for your circumstances is a clinical question, factors like your starting weight, medical history and how reliably you can maintain a daily morning routine all matter. The semaglutide injections overview lays out the injection side of that comparison if you want to read both before deciding.

Both forms act on the same GLP-1 receptor pathway: slowing gastric emptying, increasing the feeling of fullness and reducing appetite. The mechanism is shared even if the delivery route differs. The NHS semaglutide medicines page provides a patient-level summary of how it works and what to expect.

Are the side effects different when you skip the injection?

The side-effect profile is broadly similar because the active compound is the same. Gastrointestinal effects (nausea, loose stools, indigestion and reduced appetite) are the most commonly reported with both forms. In the OASIS 4 trial, around 74% of participants taking the tablet reported a gastrointestinal side effect at some point, compared with roughly 42% in the placebo group; most were mild to moderate and tended to ease as the body adjusted, particularly after dose increases settled.

The tablet does remove injection-site reactions entirely, which is one practical advantage for people who experience local redness or bruising at the needle site. If you have been curious about the injection technique involved with the pen, the guide to injecting semaglutide explains what it involves, useful context even if you are leaning toward the tablet. If you are switching from the injection and want to understand the steps involved in preparing the device, our guide to priming the Wegovy pen without a needle walks through the process clearly. The main tablet-specific discipline is the morning timing: the absorption window is narrow, so taking it with food, or too close to other oral medicines, reduces how much reaches your bloodstream.

As with all semaglutide forms, serious but infrequent risks exist. Pancreatitis is one: severe stomach pain that radiates to the back, with or without vomiting, warrants urgent medical attention. Suspected side effects from any medicine can be reported via the MHRA Yellow Card scheme. Pregnancy, breastfeeding and trying to conceive are contraindications for both tablet and injection forms; anyone in these situations should not use semaglutide. The same applies to under-18s, who are not covered by the licence. Your prescriber will go through your full history before any form is approved for you.

How do you actually get a semaglutide tablet on prescription in the UK?

Wegovy tablets are a prescription-only medicine. There is no over-the-counter route, and buying semaglutide in any form from a seller who does not require a prescription is illegal and carries serious safety risks, the MHRA has warned repeatedly about counterfeit products circulating online. Any legitimate supplier should be verifiable on the GPhC pharmacy register before you share any personal or medical information with them.

The NHS does not currently fund Wegovy tablets; a NICE appraisal would be required before NHS commissioning begins, and none has yet been published. Private prescription is currently the only route. For context on what private semaglutide treatment typically costs and what those prices do and do not include, the Wegovy prices page gives a factual breakdown. Broadly, licensed eligibility for the tablet mirrors the injection: adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure or dyslipidaemia, alongside a reduced-calorie diet and increased activity.

At nume, every consultation is reviewed the same day by a GPhC-registered Independent Prescriber, a real clinician reading your answers, not automated software. If the tablet is clinically suitable, treatment is dispatched the same day for orders placed before 12pm, arriving free the next working day in plain, unbranded packaging. If you would like to explore whether the oral form suits your situation, you can start your free consultation and let our prescribers guide the decision from there.